Résultats de la recherche - Maureen A. Zivanovic
- Résultat(s) 1 - 2 résultats de 2
-
1
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy par Tim Illidge, M. Bayne, Nicholas Brown, S. Chilton, Mark S. Cragg, Martin J. Glennie, Yong Du, Valerie Lewington, James Smart, James Thom, Maureen A. Zivanovic, Peter Johnson
Publié 2008Artigo -
2
Fractionated <sup>90</sup>Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment Ac... par Tim Illidge, Sam Mayes, Ruth Pettengell, Andrew Bates, M. Bayne, John Radford, W. David J. Ryder, Steven Le Gouill, Fabrice Jardin, Jill Tipping, Maureen A. Zivanovic, Françoise Kraeber‐Bodéré, Manuel Bardiès, Caroline Bodet‐Milin, Emmanuel Malek, D. Huglo, Franck Morschhauser
Publié 2013Artigo
Outils de recherche:
Sujets similaires
Antibody
Gastroenterology
Immunology
Internal medicine
Lymphoma
Medicine
Monoclonal antibody
Radioimmunotherapy
Rituximab
Chemotherapy
Clinical endpoint
Clinical trial
Dosing
Environmental health
Follicular lymphoma
Ibritumomab tiuxetan
International Prognostic Index
Nuclear medicine
Oncology
Phases of clinical research
Population
Surgery
Toxicity